Marina Persson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Persson has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jessica Hoffmann Relvas
Department of Internal Medicine, Conjunto Hospitalar do Mandaqui, São Paulo, Brazil
3 shared publications - Jorge Eduardo Persson
Department of Medicine, Universidade do Extremo Sul Catarinense, Criciúma, Brazil
3 shared publications - Patricia Viana
University of the Extreme South of Santa Catarina Criciúma Brazil
3 shared publications - Thamiris Dias Delfino Cabral
Department of Otolaryngology Federal Hospital of Bonsucesso Rio de Janeiro Brazil
2 shared publications - Artur Menegaz de Almeida
Federal University of Mato Grosso, Sinop, Brazil
1 shared publication - Camila Veronica Souza Freire
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- 9 May 2024
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 57 (6) , 929-935
Dual Antiplatelet Therapy vs Alteplase in Adult Patients with Acute Minor Ischemic Stroke: A Systematic Review and Meta-Analysis
The efficacy and safety of dual antiplatelet therapy (DAPT) relative to intravenous (IV) alteplase in patients with acute minor ischemic stroke are insufficiently established. Therefore, we aimed to perform a meta-analysis to compare DAPT with IV alteplase in patients with acute minor stroke. MEDLINE, Embase, and Cochrane were searched for studies comparing DAPT with IV alteplase in patients with minor stroke. Functional and safety outcomes in 90 days were analyzed. Statistical analysis was performed using Rstudio 4.3.1. Subanalyses were performed restricted to non-disabling minor strokes and NIHSS score ≤ 3. PROSPERO (CRD42023440986). We included five studies with a total of 6,340 patients, of whom 4,050 (63.9%) received DAPT. The follow-up period for all included studies was 90 days. There was no significant difference for individual outcomes of mRS 0–1 (OR 1.26; 95% CI 0.85–1.89; p = 0.25), mRS 0–2 (OR 0.99; 95% CI 0.69–1.43; p = 0.97), or all-cause mortality (OR 0.80; 95% CI 0.20–3.13; p = 0.75) between groups. Symptomatic intracranial hemorrhage (sICH) was significantly lower (OR 0.11; 95% CI 0.003–0.36; p < 0.001) in patients treated with DAPT compared with IV alteplase. In terms of mRS 0–1 and mRS 0–2, we found no significant difference in both subgroup analyses. We found no statistically significant difference between DAPT and IV alteplase regarding functional outcome (mRS scores of 0–1 and 0–2) or all-cause mortality at 90 days in patients with minor ischemic stroke. Additionally, DAPT was associated with a significantly lower rate of sICH. Graphical Abstract
- 9 May 2024
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 57 (6) , 929-935
Dual Antiplatelet Therapy vs Alteplase in Adult Patients with Acute Minor Ischemic Stroke: A Systematic Review and Meta-Analysis
The efficacy and safety of dual antiplatelet therapy (DAPT) relative to intravenous (IV) alteplase in patients with acute minor ischemic stroke are insufficiently established. Therefore, we aimed to perform a meta-analysis to compare DAPT with IV alteplase in patients with acute minor stroke. MEDLINE, Embase, and Cochrane were searched for studies comparing DAPT with IV alteplase in patients with minor stroke. Functional and safety outcomes in 90 days were analyzed. Statistical analysis was performed using Rstudio 4.3.1. Subanalyses were performed restricted to non-disabling minor strokes and NIHSS score ≤ 3. PROSPERO (CRD42023440986). We included five studies with a total of 6,340 patients, of whom 4,050 (63.9%) received DAPT. The follow-up period for all included studies was 90 days. There was no significant difference for individual outcomes of mRS 0–1 (OR 1.26; 95% CI 0.85–1.89; p = 0.25), mRS 0–2 (OR 0.99; 95% CI 0.69–1.43; p = 0.97), or all-cause mortality (OR 0.80; 95% CI 0.20–3.13; p = 0.75) between groups. Symptomatic intracranial hemorrhage (sICH) was significantly lower (OR 0.11; 95% CI 0.003–0.36; p < 0.001) in patients treated with DAPT compared with IV alteplase. In terms of mRS 0–1 and mRS 0–2, we found no significant difference in both subgroup analyses. We found no statistically significant difference between DAPT and IV alteplase regarding functional outcome (mRS scores of 0–1 and 0–2) or all-cause mortality at 90 days in patients with minor ischemic stroke. Additionally, DAPT was associated with a significantly lower rate of sICH. Graphical Abstract
- Top Cited Papers
- 17 January 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (2) , 740-748
Perioperative or Postoperative Probiotics Reduce Treatment-Related Complications in Adult Colorectal Cancer Patients Undergoing Surgery: A Systematic Review and Meta-analysis
Purpose This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to assess the efficacy of perioperative or postoperative probiotics as a therapeutic approach for managing colorectal cancer treatment–related complications in patients undergoing surgery, with or without adjuvant therapy. Methods MEDLINE, Embase, and Scopus databases were searched. Results Ten RCTs with 1276 patients were included. There was a significant decrease in the incidence of diarrhea (odds ratio (OR) 0.42; 95% CI 0.31 to 0.55; p < 0.001), surgical site infection (OR 0.44; 95% CI 0.22 to 0.89; p = 0.023), urinary infection (OR 0.43; 95% CI 0.20 to 0.91; p = 0.028), pulmonary infection (OR 0.30; 95% CI 0.15 to 0.60; p < 0.001), abdominal distention (OR 0.43; 95% CI 0.25 to 0.76; p = 0.004), length of ATB therapy (mean difference (MD) − 1.66 days; 95% CI − 2.13 to − 1.19 days; p < 0.001), and duration of postoperative pyrexia (MD − 0.80 days; 95% CI − 1.38 to − 0.22 days; p = 0.007) in the probiotic group. Nevertheless, length of hospital stay, time to first defecation, and time to first solid diet were not different between groups. Conclusion Our findings suggest that perioperative or postoperative probiotics is effective for reducing treatment-related complications in patients with colorectal cancer undergoing surgery, with a lower rate of adverse events.
- 17 January 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (2) , 740-748
Top Cited PapersPerioperative or Postoperative Probiotics Reduce Treatment-Related Complications in Adult Colorectal Cancer Patients Undergoing Surgery: A Systematic Review and Meta-analysis
Purpose This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to assess the efficacy of perioperative or postoperative probiotics as a therapeutic approach for managing colorectal cancer treatment–related complications in patients undergoing surgery, with or without adjuvant therapy. Methods MEDLINE, Embase, and Scopus databases were searched. Results Ten RCTs with 1276 patients were included. There was a significant decrease in the incidence of diarrhea (odds ratio (OR) 0.42; 95% CI 0.31 to 0.55; p < 0.001), surgical site infection (OR 0.44; 95% CI 0.22 to 0.89; p = 0.023), urinary infection (OR 0.43; 95% CI 0.20 to 0.91; p = 0.028), pulmonary infection (OR 0.30; 95% CI 0.15 to 0.60; p < 0.001), abdominal distention (OR 0.43; 95% CI 0.25 to 0.76; p = 0.004), length of ATB therapy (mean difference (MD) − 1.66 days; 95% CI − 2.13 to − 1.19 days; p < 0.001), and duration of postoperative pyrexia (MD − 0.80 days; 95% CI − 1.38 to − 0.22 days; p = 0.007) in the probiotic group. Nevertheless, length of hospital stay, time to first defecation, and time to first solid diet were not different between groups. Conclusion Our findings suggest that perioperative or postoperative probiotics is effective for reducing treatment-related complications in patients with colorectal cancer undergoing surgery, with a lower rate of adverse events.
- Open Access
- 23 November 2023
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 57 (1) , 25-35
Prothrombin Complex Concentrate versus Fresh Frozen Plasma in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis
Patricia Viana, Jessica Hoffmann Relvas, M.D., Marina Persson, M.D., Thamiris Dias Delfino Cabral, M.D., Jorge Eduardo Persson, Jessica Sales de Oliveira, Paulo Bonow, M.D., Camila Veronica Souza Freire, M.D., Sara Amaral, M.D.. J Chest Surg 2024;57:25-35. https://doi.org/10.5090/jcs.23.081
- 23 November 2023
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 57 (1) , 25-35
Open AccessProthrombin Complex Concentrate versus Fresh Frozen Plasma in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis
Patricia Viana, Jessica Hoffmann Relvas, M.D., Marina Persson, M.D., Thamiris Dias Delfino Cabral, M.D., Jorge Eduardo Persson, Jessica Sales de Oliveira, Paulo Bonow, M.D., Camila Veronica Souza Freire, M.D., Sara Amaral, M.D.. J Chest Surg 2024;57:25-35. https://doi.org/10.5090/jcs.23.081